Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results
-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market
-Advanced regulatory and seed scale-up program for omega-3 Camelina
-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada
-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update
Related news for (YTEN)
- Yield10 Bioscience Announces Second Quarter 2024 Financial Results
- Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
- Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina
- Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label
- Yield10 Bioscience Announces First Quarter 2024 Financial Results